Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68-NGUL and Lu-177-DGUL in mCRPC
NCT05547061Phase 2Completed
- Sponsor
- CellBion
- Start
- Apr 2021
- Primary completion
- Jul 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label trial of Lutetium (177Lu) DGUL in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by CellBion. Primary endpoint: Objective Response Rate according to RECIST 1.1 up to 36 months. Started Apr 2021; status: completed.
02
Drugs
Lutetium (177Lu) DGUL
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05547061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547061.